Nasdaq · Biotech stocks database

TSHA — Taysha Gene Therapies Inc.

TSHA (Taysha Gene Therapies Inc.) stock: $5.02, $1.64B market cap, $455.4M cash, $1.23B EV, $1.79B fully diluted market cap. Next expected readout: Nov-28. Lead program: TSHA-102 (Rett Syndrome), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$5.02

Market cap

$1,635.7M

Cash

$455.4M

Enterprise value

$1,229.5M

Balance sheet

Cash	$455.4M
Debt	$49.3M
Net cash	$406.2M
Enterprise value	$1,229.5M
Basic shares	325.3M shares
Fully diluted shares	356.3M shares
Fully diluted market cap	$1,788.7M
Cash per share	$1.40

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TSHA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	TSHA-102	Phase 3	Rett Syndrome	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	TSHA-102
Lead indication	Rett Syndrome
Lead phase	Phase 3
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05606614	Phase 3	Active, not recruiting	Sponsor	TSHA	—	Rett Syndrome	—
NCT07480564	Phase 3	Active, not recruiting	Sponsor	TSHA	—	Rett Syndrome	—
NCT06152237	Phase 2	Active, not recruiting	Sponsor	TSHA	—	Rett Syndrome	—
NCT04798235	Phase 2	Active, not recruiting	Collaborator	Dr. Anupam Sehgal	—	Infantile GM2 Gangliosidosis (Disorder)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Taysha Gene Therapies, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	13,560,258	-119,990	0.79%	2026-08-14
Baker Bros. Advisors	4,004,756	no change	0.14%	2026-08-14
ADAR1 Capital Management	3,040,466	+61,037	0.97%	2026-08-14
OrbiMed Advisors	2,000,000	+2,000,000	0.26%	2026-08-14
Sphera Biotech	250,000	+250,000	0.24%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego